Neutralizing Human Antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 Isolated from a Human Synthetic Fab Phage Display Library.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
15 Feb 2021
Historique:
received: 18 01 2021
revised: 10 02 2021
accepted: 12 02 2021
entrez: 6 3 2021
pubmed: 7 3 2021
medline: 18 3 2021
Statut: epublish

Résumé

Since it was first reported in Wuhan, China, in 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic outbreak resulting in a tremendous global threat due to its unprecedented rapid spread and an absence of a prophylactic vaccine or therapeutic drugs treating the virus. The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein is a key player in the viral entry into cells through its interaction with the angiotensin-converting enzyme 2 (ACE2) receptor protein, and the RBD has therefore been crucial as a drug target. In this study, we used phage display to develop human monoclonal antibodies (mAbs) that neutralize SARS-CoV-2. A human synthetic Fab phage display library was panned against the RBD of the SARS-CoV-2 spike protein (SARS-2 RBD), yielding ten unique Fabs with moderate apparent affinities (

Identifiants

pubmed: 33671877
pii: ijms22041913
doi: 10.3390/ijms22041913
pmc: PMC7918989
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0
Antibodies, Neutralizing 0
Immunoglobulin Fab Fragments 0
Immunoglobulin G 0
Peptide Library 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Trends Immunol. 2020 May;41(5):355-359
pubmed: 32249063
J Gen Virol. 2000 Jul;81(Pt 7):1727-35
pubmed: 10859378
Cell Mol Immunol. 2020 Jun;17(6):613-620
pubmed: 32203189
Viruses. 2020 Nov 11;12(11):
pubmed: 33187074
Proc Natl Acad Sci U S A. 2020 Nov 24;117(47):29832-29838
pubmed: 33139569
J Mol Biol. 2000 Feb 11;296(1):57-86
pubmed: 10656818
Science. 2020 Aug 21;369(6506):1010-1014
pubmed: 32540901
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
J Virol. 2018 Apr 27;92(10):
pubmed: 29514901
Chem Asian J. 2019 Nov 18;14(22):3962-3968
pubmed: 31389664
Sci Rep. 2020 Dec 22;10(1):22370
pubmed: 33353972
Cell. 2020 Jul 9;182(1):73-84.e16
pubmed: 32425270
Antibodies (Basel). 2019 Jul 31;8(3):
pubmed: 31544848
Lancet. 2020 Feb 15;395(10223):470-473
pubmed: 31986257
Nat Med. 2020 Sep;26(9):1422-1427
pubmed: 32651581
Cell Res. 2017 Jan;27(1):119-129
pubmed: 28008928
Nature. 2020 Jul;583(7815):290-295
pubmed: 32422645
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Nat Commun. 2020 May 4;11(1):2251
pubmed: 32366817
Nat Biotechnol. 2005 Sep;23(9):1105-16
pubmed: 16151404
Antib Ther. 2020 Jul;3(3):205-212
pubmed: 33215063
Science. 2020 Aug 7;369(6504):650-655
pubmed: 32571838
Nat Rev Drug Discov. 2016 May;15(5):327-47
pubmed: 26868298
Annu Rev Virol. 2016 Sep 29;3(1):237-261
pubmed: 27578435
Nat Biotechnol. 2011 Mar;29(3):245-54
pubmed: 21390033
Thorax. 2004 Mar;59(3):252-6
pubmed: 14985565
J Virol. 2012 Mar;86(5):2856-8
pubmed: 22205743
Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8738-43
pubmed: 26124093
Nature. 2016 Mar 3;531(7592):118-21
pubmed: 26935699
Science. 2020 Aug 21;369(6506):1014-1018
pubmed: 32540904
Int J Biol Sci. 2020 Mar 15;16(10):1718-1723
pubmed: 32226289
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Int J Biol Macromol. 2020 Mar 15;147:369-375
pubmed: 31926922
Cell Mol Immunol. 2020 Jun;17(6):647-649
pubmed: 32313207
Antimicrob Agents Chemother. 2012 Sep;56(9):4569-82
pubmed: 22664969
Int J Mol Sci. 2020 Sep 01;21(17):
pubmed: 32883029
Science. 1985 Jun 14;228(4705):1315-7
pubmed: 4001944
Annu Rev Immunol. 1994;12:433-55
pubmed: 8011287
Virol J. 2005 Aug 22;2:69
pubmed: 16115318
Front Med. 2017 Dec;11(4):462-470
pubmed: 29159596
mBio. 2012 Nov 20;3(6):
pubmed: 23170002
EMBO J. 1994 Jul 15;13(14):3245-60
pubmed: 8045255
Nat Commun. 2020 Aug 27;11(1):4303
pubmed: 32855401
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496
pubmed: 32253318
Infection. 2020 Oct;48(5):665-669
pubmed: 32737833
Nature. 2020 Dec;588(7839):682-687
pubmed: 33045718
Curr Med Chem. 2008;15(10):997-1005
pubmed: 18393857
MAbs. 2020 Jan 1;12(1):1778435
pubmed: 32544372
Viruses. 2020 May 06;12(5):
pubmed: 32384820
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Respir Res. 2020 Aug 27;21(1):224
pubmed: 32854739
Science. 2020 Dec 18;370(6523):1464-1468
pubmed: 33184236
J Mol Biol. 2003 Jan 17;325(3):531-53
pubmed: 12498801
Trends Pharmacol Sci. 2020 Nov;41(11):815-829
pubmed: 32829936

Auteurs

Yu Jung Kim (YJ)

New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.

Min Ho Lee (MH)

New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.

Se-Ra Lee (SR)

New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.

Hyo-Young Chung (HY)

New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.

Kwangmin Kim (K)

New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.

Tae Gyu Lee (TG)

New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.

Dae Young Kim (DY)

New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH